Saxagliptin is a type 2 diabetes medication that stimulates the pancreas to produce more insulin after meals. It was jointly developed by AstraZeneca and Bristol-Myers Squibb. It is a dipeptidyl peptidase-4 (DPP-IV) inhibitor. On July 31, 2009, AstraZeneca and Bristol-Myers Squibb jointly developed a new type 2 diabetes drug, saxagliptin (Onglyza), which was approved by the US FDA for listing once a day to treat adult type 2 diabetes while controlling diet, exercise. The most common side effects were upper respiratory tract infection, urinary tract infection and headache, other side effects included allergic-like reactions such as rash and hives. Mechanism of Action Saxagliptin works by blocking the degradation of GLP-1, a hormone naturally produced in the intestine after ingestion of food that regulates insulin secretion and enhances the availability of glucose in surrounding tissues . Saxagliptin alone can improve blood sugar control, and the combination with metformin, sulfonylureas, and thiazolidinediones can enhance the efficacy, and its risk of causing hypoglycemia is less, and the adverse reactions are similar to placebo, showing better results. tolerance.